Miguel de Almeida Fuzeta

Dr. Miguel de Almeida Fuzeta

Instituto Superior Técnico, Lisbon, Lisboa, Portugal
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2022 in Bioengineering
Verified
Journal Article
Open access
PDF file
MFMiguel de Almeida Fuzeta
Miguel de Almeida Fuzeta
PGPedro Espirito Santo Prates Gonçalves
Pedro Espirito Santo Prates Gonçalves
AFAna Fernandes-Platzgummer
Ana Fernandes-Platzgummer
Joaquim M.S. CabralJoaquim M.S. Cabral
Joaquim M.S. Cabral
Nuno BernardesNuno Bernardes
Nuno Bernardes
CSCláudia Lobato da Silva
Cláudia Lobato da Silva
Extracellular vesicles (EVs) have been the focus of great attention over the last decade, considering their promising application as next-generation therapeutics. EVs have emerged as relevant mediators of intercellular communication, being associated with multiple physiological processes, but also in the pathogenesis of several diseases. Given their natural ability to shuttle messages between cells, EVs have been explored both as inherent therapeutics in regenerative medicine and as drug delivery vehicles targeting multiple diseases. However, bioengineering strategies are required to harness the full potential of EVs for therapeutic use. For that purpose, a good understanding of EV biology, from their biogenesis to the way they are able to shuttle messages and establish interactions with recipient cells, is needed. Here, we review the current state-of-the-art on EV biology, complemented by representative examples of EVs roles in several pathophysiological processes, as well as the intrinsic therapeutic properties of EVs and paradigmatic strategies to produce and develop engineered EVs as next-generation drug delivery systems.

22 April 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
CMCláudia Raquel Marques
Cláudia Raquel Marques
MFMiguel de Almeida Fuzeta
Miguel de Almeida Fuzeta
RCRaquel Medina dos Santos Cunha
Raquel Medina dos Santos Cunha
Joana Pereira-SousaJoana Pereira-Sousa
Joana Pereira-Sousa
DSDeolinda Silva
Deolinda Silva
António SalgadoAntónio Salgado
António Salgado
Parkinson’s disease (PD) is the second most common neurodegenerative disorder and is characterized by the degeneration of the dopamine (DA) neurons in the substantia nigra pars compacta, leading to a loss of DA in the basal ganglia. The presence of aggregates of alpha-synuclein (α-synuclein) is seen as the main contributor to the pathogenesis and progression of PD. Evidence suggests that the secretome of mesenchymal stromal cells (MSC) could be a potential cell-free therapy for PD. However, to accelerate the integration of this therapy in the clinical setting, there is still the need to develop a protocol for the large-scale production of secretome under good manufacturing practices (GMP) guidelines. Bioreactors have the capacity to produce large quantities of secretomes in a scalable manner, surpassing the limitations of planar static culture systems. However, few studies focused on the influence of the culture system used to expand MSC, on the secretome composition. In this work, we studied the capacity of the secretome produced by bone marrow-derived mesenchymal stromal cells (BMSC) expanded in a spinner flask (SP) and in a Vertical-Wheel™ bioreactor (VWBR) system, to induce neurodifferentiation of human neural progenitor cells (hNPCs) and to prevent dopaminergic neuron degeneration caused by the overexpression of α-synuclein in one Caenorhabditis elegans model of PD. Results showed that secretomes from both systems were able to induce neurodifferentiation, though the secretome produced in the SP system had a greater effect. Additionally, in the conditions of our study, only the secretome produced in SP had a neuroprotective potential. Lastly, the secretomes had different profiles regarding the presence and/or specific intensity of different molecules, namely, interleukin (IL)-6, IL-4, matrix metalloproteinase-2 (MMP2), and 3 (MMP3), tumor necrosis factor-beta (TNF-β), osteopontin, nerve growth factor beta (NGFβ), granulocyte colony-stimulating factor (GCSF), heparin-binding (HB) epithelial growth factor (EGF)-like growth factor (HB-EGF), and IL-13. Overall, our results suggest that the culture conditions might have influenced the secretory profiles of cultured cells and, consequently, the observed effects. Additional studies should further explore the effects that different culture systems have on the secretome potential of PD.

31 March 2026 in Trends in Biotechnology
Verified
Journal Article
Closed access
AMAna Meliciano
Ana Meliciano
JJJoão Jacinto
João Jacinto
CFCatarina Freitas
Catarina Freitas
MCMarta H.G. Costa
Marta H.G. Costa
MFMiguel de Almeida Fuzeta
Miguel de Almeida Fuzeta
MSMargarida Serra
Margarida Serra